Patent termPTEPharmaceuticals

Patent term extension: how PTE restores lost time

By Ipiry TeamPublished August 30, 202610 min read

Short answer

Patent Term Extension restores patent term lost to FDA regulatory review for pharmaceutical and medical device patents. It adds up to five years, capped at 14 years of remaining term from the date of FDA approval, and only one patent per approved product may be extended. The application must be filed within 60 days of approval, a deadline that cannot be extended. PTE is separate from Patent Term Adjustment and the two can apply to the same patent.

Patent term extension exists because a drug patent runs for twenty years while the product cannot legally be sold for much of it.

FDA review consumes term. A compound patented in 2010 and approved in 2021 spent eleven of its twenty years generating no revenue.

PTE gives some of that back — up to five years, under 35 U.S.C. 156, added to the end of the patent's term.

But the constraints are severe. One patent per product, a 14-year cap, and a 60-day filing deadline that cannot be extended.

Why the extension exists

A patent term runs from filing, but a regulated product cannot be sold until it is approved, and the gap between those two events is often more than a decade.

Stage	Typical duration	Patent term consumed
Filing to grant	2–5 years	Yes
Preclinical and clinical testing	6–8 years	Yes
FDA review of the marketing application	1–2 years	Yes
Post-approval marketing	Whatever remains	The only revenue period

A compound filed in 2010 and approved in 2021 had nine years of term left, on a twenty-year patent, to recover development costs that ran into the hundreds of millions.

Hatch-Waxman was the bargain struck around that. Sponsors received term restoration for regulatory delay; generic manufacturers received an abbreviated approval pathway and a safe harbour for pre-expiry development work.

Which is why the 14-year cap exists. The restoration is designed to guarantee a period of post-approval exclusivity, not to reward long patents with longer ones — and the cap is what enforces that.

What PTE is and is not

	Patent Term Adjustment	Patent Term Extension
Compensates for	USPTO examination delay	FDA regulatory delay
Statute	35 U.S.C. 154(b)	35 U.S.C. 156
Technologies	Any	Regulated products only
Applied for?	No — automatic	Yes, within 60 days
Maximum	No fixed cap	5 years
Additional cap	—	14 years remaining from approval
Claims affected	All	Only approved product and uses
Can both apply?	Yes	Yes

They stack. A pharmaceutical patent can carry substantial PTA for slow examination and then PTE for slow approval, running well past twenty years from filing.

PTE is narrower in what it extends. PTA lengthens the whole patent. PTE extends only the claims covering the approved product and its approved uses — other claims expire on the original date.

The interim extension

A patent can expire while FDA review is still running, and there is a mechanism for that narrow case.

	Interim extension
When	The patent would expire before approval is granted
Applied for	During the review period, before expiry
Duration	One year at a time, renewable
Maximum	Up to five annual interim extensions
Relationship to PTE	A holding measure; the full PTE application still follows approval

It is applied for during review, not after. An interim extension cannot resurrect a patent that has already expired, so the application has to be made while the patent is still alive.

It does not replace the 60-day PTE application. Once approval arrives, the ordinary application must still be filed within 60 days, and interim extensions granted along the way do not extend that deadline.

The scenario is rare but expensive when missed. A patent that lapses weeks before approval takes the entire post-approval exclusivity with it, and no subsequent filing recovers it.

Eligibility

Requirement	Detail
Product type	Drug, medical device, food additive or colour additive
Patent claims	The product, a method of using it, or a method of manufacturing it
In force	Patent must not have expired when the application is filed
Not previously extended	One extension per patent
First commercial marketing	The approval must be the first permitted marketing of that product
One per product	Only one patent may be extended per approval

"First permitted commercial marketing" excludes a great deal. A new formulation or new indication for an already-approved active ingredient generally does not qualify, because the product has been marketed before.

Medical devices qualify through premarket approval, the lengthy pathway. The shorter 510(k) clearance route rarely produces enough delay to matter.

The calculation

Regulatory review period = half the testing phase + all of the approval phase.

Phase	Runs from	To	Counted
Testing	Effective date of the investigational exemption	Submission of the marketing application	Half
Approval	Submission of the marketing application	Approval	All

Then three reductions and caps apply.

Adjustment	Effect
Applicant's lack of due diligence	Subtracted day for day
Time before patent grant	Not counted
Statutory maximum	5 years
14-year cap	Total remaining term from approval cannot exceed 14 years

The 14-year cap is what usually binds, not the five-year maximum. A patent with plenty of term left at approval gets little or no extension, because it already provides close to fourteen years of post-approval exclusivity.

Worked example: the cap in action

Two patents, same five-year entitlement, different outcomes.

Patent A — granted late, long review


Non-provisional filed	March 2008
Base expiry	March 2028
PTA	400 days → April 2029
FDA approval	September 2022
Regulatory review period	7.5 years → entitlement capped at 5 years
Extended expiry	April 2034
Remaining term from approval	Sept 2022 → April 2034 = 11.6 years
14-year cap	Not exceeded
Result	Full 5 years granted — April 2034

Patent B — granted early, short review


Non-provisional filed	June 2014
Base expiry	June 2034
PTA	0 days
FDA approval	January 2023
Regulatory review period	4 years → entitlement 4 years
Extension would give	June 2038
Remaining term from approval	Jan 2023 → June 2038 = 15.4 years
14-year cap	Jan 2023 + 14 = January 2037
Result	Capped — January 2037, roughly 2.5 years granted

Patent B lost 1.5 years of entitlement to the cap. It was entitled to four years and received about two and a half, because it already had substantial term remaining at approval.

The cap is doing exactly what it was designed to do — guaranteeing a period of post-approval exclusivity rather than rewarding long patents with longer ones.

Generic entry and the extended date

The extended expiry date sets when generic competition can begin, which is why the choice of patent is a commercial decision rather than an administrative one.

Factor	Effect on generic entry
Extended patent's expiry	The operative date for the approved product
Other unextended patents	May still block, if they cover the product
Regulatory exclusivities	Run in parallel, independent of patent term
Paediatric exclusivity	Adds six months to certain periods

Patent term and regulatory exclusivity are separate systems. Data exclusivity and orphan-drug exclusivity run on their own clocks and can outlast or be outlasted by the patent, so the effective entry date is the later of the two.

Model both together. Extending a patent to a date already covered by regulatory exclusivity adds nothing commercially.

Choosing which patent to extend

One per product, and the decision is permanent.

Patent type	Typical scope	Consideration
Composition of matter	The active compound itself	Broadest; hardest to design around
Formulation	A specific delivery form	Narrower; alternative formulations exist
Method of treatment	Use for a specific indication	Narrow; other indications unprotected
Method of manufacture	Process only	Weakest against imported product

Composition patents are usually the right choice, because they are hardest to avoid. But the arithmetic can point elsewhere: a composition patent already near the 14-year cap gains little, while a later-filed formulation patent might gain the full five years.

Compare extended expiry dates, not entitlements. The question is which extended patent produces the latest useful exclusivity, and that depends on each patent's base date, its PTA, and how the cap applies to each.

Decide before the 60 days start running. The clock begins at approval, and the analysis takes longer than most sponsors allow when approval arrives.

The 60-day deadline

Statutory, and unforgiving.


Deadline	60 days from FDA approval
Extendable	No
Consequence of missing	Extension forfeited entirely
Filed with	USPTO, which consults the FDA on the review period
FDA determination	Published; can be challenged

Sixty days is short for a decision this consequential. It covers choosing which patent to extend, assembling the regulatory chronology, and preparing the application.

Prepare before approval. Sponsors who wait for the approval letter to start thinking are working against a clock that does not stop for analysis.

Interim extensions exist where a patent would expire during a long review, but they have their own requirements and do not rescue a missed 60-day deadline.

Outside the US

Jurisdiction	Mechanism	Maximum
United States	Patent Term Extension	5 years, capped at 14 from approval
Europe	Supplementary Protection Certificate	5 years, capped at 15 from first authorisation
Europe, paediatric	SPC paediatric extension	+6 months
Japan	Patent term extension	5 years
South Korea	Patent term extension	5 years
Most others	None	—

The European SPC is a separate right, not an extension of the patent, though it works the same way commercially. It is granted country by country, so a product needs SPCs filed in each market that matters.

The paediatric six months is small in percentage terms and large in absolute revenue on a successful product, which is why paediatric investigation plans are completed even where the clinical value is limited.

Filing deadlines differ everywhere. SPC applications have their own windows, and a team focused on the US 60-day deadline can miss them.

Where PTE sits in the term calculation

PTE is one input among several. See how long can a patent last for the full stack, and patent term adjustment for the USPTO-delay component that applies to every technology.

And none of it matters if maintenance fees go unpaid. An extended patent is still subject to the three US maintenance fees, and 58.6% of US utility patents are abandoned before full term — see the patent survival curve. Pharmaceutical patents under extension are among the least likely to be abandoned, but the obligation does not disappear because the term was extended.

Patent term extension: the checklist

Confirm eligibility early — regulated product, patent in force, first permitted commercial marketing, not previously extended.
Identify every candidate patent covering the product, a method of using it, or a method of manufacturing it.
Calculate the extension for each candidate separately, applying both the five-year maximum and the 14-year cap.
Compare extended expiry dates, not entitlements. The cap can reverse the ranking.
Weigh scope alongside dates. A composition patent expiring earlier may still beat a formulation patent expiring later.
Do the analysis before approval arrives. Sixty days is not enough time to start from scratch.
Diarise the 60-day deadline from the approval date the moment approval is granted. It cannot be extended.
Assemble the regulatory chronology in advance — investigational exemption date, application submission, approval.
Check the FDA's published review period determination and challenge it if the dates are wrong.
Track SPC and foreign extension deadlines separately. They have their own windows and will not wait for the US filing.

Common questions

What is patent term extension?

A restoration of patent term lost while a product awaited FDA approval, under 35 U.S.C. 156 as introduced by the Hatch-Waxman Act. It applies to pharmaceuticals, medical devices, and food and colour additives. It adds up to five years, subject to a cap of 14 years of remaining term from the approval date.

How is patent term extension calculated?

The regulatory review period is half the testing phase plus all of the approval phase. Any time the applicant failed to act with due diligence is subtracted. The result is added to the patent's expiry date, then capped at five years and at 14 years of remaining term from approval.

What is the difference between PTE and PTA?

PTA compensates for USPTO examination delay and is available to any technology, calculated automatically and printed on the patent. PTE compensates for FDA regulatory delay, applies only to regulated products, and must be applied for. They address different delays and can both apply to the same patent.

How long do I have to apply for PTE?

Sixty days from the date of FDA approval. The deadline is statutory and cannot be extended. Missing it forfeits the extension entirely regardless of how much term was lost, which makes it one of the least forgiving deadlines in patent practice.

Can more than one patent be extended per product?

No. Only one patent per approved product may receive an extension, so a sponsor holding composition, formulation and method-of-treatment patents must choose. The choice is commercially significant and is made under the 60-day deadline.

What is the 14-year cap?

The extended patent cannot provide more than 14 years of remaining term measured from the date of FDA approval. Where a patent already has substantial term left at approval, the cap reduces or eliminates the extension even though the full five years would otherwise be available.

Which patents are eligible for PTE?

A patent claiming the approved product, a method of using it, or a method of manufacturing it. The patent must be in force when the application is filed, must not have been previously extended, and the approval must be the first permitted commercial marketing of that product.

Does PTE extend all the claims of a patent?

No. The extension applies only to claims covering the approved product and approved uses. Other claims in the same patent expire on the original date, so a broad patent can have some claims extended and others not.

Does Europe have patent term extension?

Supplementary Protection Certificates perform the same function for pharmaceutical and plant protection products, adding up to five years capped at 15 years from first authorisation. A further six months is available where an agreed paediatric investigation plan is completed.

Can PTE be applied to a medical device patent?

Yes, where the device went through a regulatory review that delayed marketing — typically premarket approval rather than the shorter 510(k) clearance pathway. The same calculation, caps and 60-day deadline apply.

Who decides how much PTE is granted?

The USPTO grants the extension but relies on the FDA to determine the length of the regulatory review period. The FDA publishes its determination, which can be challenged, and the USPTO then applies the statutory caps and any due diligence reductions.

Does PTE affect generic entry?

Directly. The extended expiry date on the chosen patent sets when generic competition can begin for the approved product, which is why the choice of which patent to extend is among the most consequential decisions a sponsor makes.

How long can a patent last?

The theoretical maximum term of a US patent — how PTA, PTE and a provisional year stack, what the record holders look like, and why almost nothing gets close.

Patent term adjustment: how PTA works and how to check yours

PTA compensates for USPTO delay and is printed on the face of your patent. How the A, B and C delays are calculated, what applicant delay costs, and how to dispute a wrong figure.

Patent expiration date: how to calculate it

The 20-year date is the starting point, not the answer. How PTA, PTE, terminal disclaimers and unpaid fees move a patent's real expiration date, and how to check any patent.

What is your patent worth?

Free AI valuation in 60 seconds, benchmarked against 652,000 KPSS patent value records and the Ipiry Patent Survival Curve.

Value My Patent Free →Takes 60 seconds. No credit card required.